Cyproheptadine hydrochloride

Key Product Details

Product Description

Non-selective 5HT₂ antagonist, migraine prophylactic. Also SETD7/9 inhibitor (IC₅₀ = 1μM). Decreases expression and increases degradation of estrogen receptor (ER) α in breast tumor MCF7 cells. Inhibits growth of MCF7 xenografts in mice.

Product Specifications for Cyproheptadine hydrochloride

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for Cyproheptadine hydrochloride

The following data is based on the product molecular weight 323.86.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	3.09 mL	15.44 mL	30.88 mL
5 mM	0.62 mL	3.09 mL	6.18 mL
10 mM	0.31 mL	1.54 mL	3.09 mL
50 mM	0.06 mL	0.31 mL	0.62 mL

Calculators

Background References

References are publications that support the biological activity of the product.

• Moran Inhibitory 5-hydroxytryptamine receptors involved in pressor effects obtained by stimulation of sympathetic outflow from spinal cord in pithed rats. Br.J.Pharmacol. 1994 PMID: 7889292
• Takemoto Identification of cyprohept. as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates estrogen-dependent transcription. J.Med.Chem. 2016 PMID: 27088648
• Hoyer VII. International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol.Rev. 1994 PMID: 7938165

Product Documents for Cyproheptadine hydrochloride